Indian Generic Group Tells New Department Of Pharmaceuticals That Industry Is Under Attack By Multinationals
This article was originally published in PharmAsia News
Executive Summary
With the setting up of a new Department of Pharmaceuticals, the Indian Pharmaceutical Alliance, a powerful lobby of the top 11 Indian generic drug makers, has upped its ante against brand-drug multinational companies
You may also be interested in...
Indian Pharma Lobby Begins Fresh Offensive For Cap On Foreign Investments Into Domestic Companies
MUMBAI - As India's commerce and finance ministries wrangle over the viability of capping investments by global pharmaceutical companies into Indian generic firms, the Indian Pharmaceutical Alliance led a new offensive urging the government to tighten investment regulations
Indian Pharma Lobby Begins Fresh Offensive For Cap On Foreign Investments Into Domestic Companies
MUMBAI - As India's commerce and finance ministries wrangle over the viability of capping investments by global pharmaceutical companies into Indian generic firms, the Indian Pharmaceutical Alliance led a new offensive urging the government to tighten investment regulations
Ranbaxy Alleges Rivals Of Meddling With Daiichi Sankyo Deal; U.S. House Committee Enters Fray
MUMBAI - India's leading drug maker Ranbaxy Laboratories has alleged that global big pharma players are trying to scuttle its acquisition by Daiichi Sankyo. U.S. FDA and the U.S. Department of Justice's probe of Ranbaxy is part of a larger battle against the company, CEO Malvinder Singh said in a television interview on Friday, indicating that vested interests in the global industry were trying to stall the deal